Year: 2013
Type: article
Abstract: Summary: Resistance to RAF inhibitors is generally accompanied by reactivation of extracellular signal-regulated kinase (ERK) signaling. SCH772984, a selective, ATP-competitive inhibitor of ERK1 and ERK2, is effective in BRAF-mutant models in which resistance is the result of ERK reactivation. SCH772984 may also have a role in the treatment of tumors in which ERK is dysregulated by mutant RAS, NF1, or activated receptor tyrosine kinases, settings in which current RAF inhibitors are ineffective. Cancer Discov; 3(7); 719–21. ©2013 AACR. See related article by Morris et al., p. 742
Source: Cancer Discovery
Authors: Moriah H. Nissan, Neal Rosen, David B. Solit
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2156070073